Patients with ALK fusion NSCLC who acquire compound (≥2) ALK TKD mutations during lorlatinib treatment, however, have been found to show markedly decreased sensitivity to lorlatinib and clinical progression13,16–21. This evidence concerns the gene ALK and non-small cell lung carcinoma.